AVBP at a glance
ArriVent BioPharma, Inc. (AVBP, SEC CIK 1868279) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as June 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ArriVent BioPharma, Inc. (AVBP) shares worth $480.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by HILLHOUSE INVESTMENT MANAGEMENT, LTD. on December 10, 2025 of 555,555 shares at $23.37 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $480.9M · +2 vs prior quarter
- Latest 8-K
- Aug 12, 2026
- Item 2.02 · Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; no products approved or product-sales revenue generated
- Operating margin not applicable; operating loss $52.7M vs $33.6M YoY
- R&D highest program: early-stage programs $13.4M, up $9.8M YoY
- Cash, equivalents and short-term investments $373.1M at June 30, 2026
- ATM issuance $140.0M net proceeds; management expects continued losses and substantially higher R&D spending
Risk Factors
- Newly triggered USPTO ex parte reexamination of RE ’687 Patent following July 2026 request grant
- Patent protection risk from possible narrowing or cancellation of RE ’687 claims
- Intellectual-property proceedings risk from defense costs and management-resource diversion
- Competitive exposure if patent rights no longer cover product candidates or block third-party competition
AI summary of the AVBP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 furnished under Item 2.02, but not incorporated into other SEC filings
- Disclosure receives limited liability protection under Sections 11, 12(a)(2), and 18
Item EX-99.1: Item EX-99.1
- $373.1M cash and investments expected to fund operations into 2028, reducing near-term financing risk
- Firmonertinib pivotal Phase 3 topline data expected in 2H 2026, the key near-term value catalyst
Item 1.01: Entry into a Material Definitive Agreement
- Exclusive Greater China license for ARR-002 granted to Shanghai Allist, with sublicensing rights and royalty-bearing economics
- ArriVent retains ARR-002 rights outside Greater China and the right to manufacture within the territory
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected Healy, Hohneker, and Lutzker as Class II directors through the 2029 annual meeting
- Director support varied materially: Lutzker 29,495,923 votes versus Healy 18,058,285
AI summaries of AVBP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AVBP
Don't miss the next AVBP filing
- Alerts as it files. A push when AVBP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVBP, by share count.
- Ask anything. An AI agent that reads every AVBP filing and answers with sources.
AVBP alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Peterson Kristine | A | Jun 18, 2026 | 13,562 | - |
| Hohneker John | A | Jun 18, 2026 | 13,562 | - |
| Nolet Chris | A | Jun 18, 2026 | 13,562 | - |
| Parsey Merdad | A | Jun 18, 2026 | 13,562 | - |
| Kung Winston | A | Feb 2, 2026 | 140,000 | - |
| Lutzker Stuart | A | Feb 2, 2026 | 150,000 | - |
| LaChapelle Robin | A | Feb 2, 2026 | 130,000 | - |
| Yao Zhengbin | A | Feb 2, 2026 | 550,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$74.6M | -$94.3M | -$177.5M | |
| Net Income | -$69.3M | -$80.5M | -$166.3M | |
| Balance Sheet | ||||
| Total Assets | $163.1M | $274.9M | $333.2M | |
| Equity | -$153.2M | $257.7M | $307.2M | |
| ROE | 45.3% | -31.2% | -54.1% | |
| Per Share | ||||
| EPS | $-32.38 | $-2.56 | $-4.32 | |
| Cash Flow | ||||
| Operating CF | -$55.8M | -$70.2M | -$160.6M | |
Source: XBRL data in ArriVent BioPharma, Inc. (AVBP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AVBP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $480.9M |
| Q1 2026 | 24 | $268.0M |
| Q4 2025 | 23 | $233.3M |
| Q3 2025 | 21 | $192.2M |
| Q2 2025 | 18 | $155.8M |
| Q1 2025 | 14 | $94.8M |
| Q4 2024 | 10 | $126.1M |
| Q3 2024 | 7 | $24.0M |
- BlackRock+720.1K (+28%)
- D.E. Shaw & Co+503.2K (+136%)
- State Street Corp+271.6K (+19%)
- Vanguard Capital Management LLC+246.0K (+16%)
- Ameriprise Financial+201.6K (+112%)
- FMR LLC (Fidelity)−237.2K (-8%)
- Citadel Advisors LLC−9.4K (-6%)
- JPMorgan Chase & Co−187 (-0%)
- PNC Financial Services−112 (-34%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 143 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVBP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 6, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | May 11, 2026 | - | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 17, 2026 | - | Analysis | - |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 3, 2026 | - | - | |
| SC 13G | Jan 21, 2026 | - | - | |
| 10-Q | Nov 10, 2025 | Sep 30, 2025 | Analysis | |
| SC 13G | Oct 30, 2025 | - | - | |
| SC 13G | Oct 15, 2025 | - | - | |
| SC 13G | Aug 13, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AVBP SEC filings: frequently asked questions
Which institutions hold AVBP stock?
As of June 30, 2026, the largest ArriVent BioPharma, Inc. (AVBP) holders among the 13F filers tracked by SignalX were BlackRock ($112.9 million), FMR LLC (Fidelity) ($96.5 million), Vanguard Capital Management LLC ($61.7 million), State Street Corp ($58.8 million), D.E. Shaw & Co ($30.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did AVBP report in its latest 8-K?
ArriVent BioPharma, Inc. (AVBP) filed an 8-K on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 1.01 (Entry into a Material Definitive Agreement). Exhibit 99.1 furnished under Item 2.02, but not incorporated into other SEC filings.
What are the latest AVBP SEC filings?
ArriVent BioPharma, Inc. (AVBP) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on June 22, 2026.
What is AVBP's SEC CIK number?
ArriVent BioPharma, Inc. (AVBP)'s SEC Central Index Key (CIK) is 1868279. EDGAR lists every AVBP filing under that number.
Ask anything about AVBP
The research agent reads AVBP's filings, financials, insider trades and 13F holders, then answers with sources.